- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02933307
Continuous Monitoring on the General Ward
Continuous Monitoring of Vital Signs in Hospitalized Patients
Rationale: Monitoring patients' vital signs is done to detect clinical deterioration. For this, the MEWS, a scoring list comprising seven vital signs measured by nursing staff, is used. Although the MEWS provides relevant data on patients' health status, the interval measurements may not capture early deterioration of vital signs, especially during the night. As a result, unsafe situations may occur such as periods of low oxygen saturation and cardiac arrhythmias, which are known to complicate postoperative course. Besides, this way of measuring vital signs may be stressful for patients and disturbs patients' sleep. New technology such as ViSi Mobile and HealthPatch allows for remote continuous monitoring of vital signs using wearable devices transmitting relevant data to nurses and clinicians. With this, the investigators think that clinical deterioration may be detected in an early phase and reduce nurse work load and patient distress.
Objective: to investigate the feasibility of wearable devices on the general ward.
Study design: feasibility study.
Study population: adult patients hospitalized on the internal medicine ward and adult postoperative patients on the surgical ward.
Intervention: patients in the intervention groups will be randomized in one of the two groups. Patients in the group 1 will wear ViSi Mobile; patients in group 2 will wear the HealthPatch. Wearable devices will be worn for at least three days. Regular MEWS measurements take place at usual time points.
Main study parameters/endpoints: Evaluation with patient and care givers (primary outcome measure), MEWS calculations, time between alarm (continuous data) and next regular MEWS measurement (nurse), intervention by nurse after alarm, admission to ICU, complications, side effects of devices, STAI scores, and PCS scores will be documented.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will wear one device for at least three days. Devices can be uncomfortable by being heavy or the patches can start itching. More measurements by nurses can take place when indicated, for example after alarms. The participating patients will fill out the STAI on daily basis and the PCS on the last day of hospitalization. Both questionnaires will take a few minutes to complete. Patients could benefit from early detection of clinical deterioration and early corrective interventions or ICU admissions.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patient is 18 years or older on the day the informed consent will be signed.
- Patient is hospitalized on the surgical or internal medicine ward.
- MEWS measurements are required at least three times a day.
- Patient is able to speak, read and understand the local language of the investigational site, is familiar with the procedures of the study, and agrees to participate in the study program by giving oral and written informed consent prior to screening evaluations.
Exclusion Criteria:
- Frequency of MEWS measurements is less than three times a day.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Control group
Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
|
|
|
Expérimental: HealthPatch (Intervention)
Patients with HealthPatch and regular MEWS measurements
|
The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
|
|
Expérimental: ViSi Mobile (Intervention)
Patients with ViSi Mobile and regular MEWS measurements
|
ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Expectations & experiences of patients
Délai: 2-3 days after informed consent
|
Interviews of 15-20 minutes with patients after 2-3 days wearing a device or control group
|
2-3 days after informed consent
|
|
Expectations & experiences of care givers
Délai: 1 year
|
Interviews with nurses of 15-20 minutes at the end of the study.
Estimated amount of 6 nurses
|
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
MEWS scores based on continuous data and data measured by nurses
Délai: 3 times a day, up to three days.
|
3 times a day, up to three days.
|
|
|
Amount of alarms by HealthPatch or ViSi Mobile
Délai: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Time between alarm (continuous data) and next regular MEWS measurement (nurse)
Délai: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Amount of extra MEWS measurements by nurses due to alarms
Délai: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Admission to ICU (yes/no)
Délai: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Duration of ICU hospitalization in days
Délai: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Complications caused by disease or surgical procedure
Délai: during 2-3 days when the patient participates in this study
|
during 2-3 days when the patient participates in this study
|
|
|
Adverse events caused by devices
Délai: during 2-3 days when the patient wears a device
|
E.g. Itch or redness
|
during 2-3 days when the patient wears a device
|
|
Technical failures of devices (artifacts: a period longer than 1 minute the device does not measure vital parameters)
Délai: during 2-3 days when the patient wears a device
|
during 2-3 days when the patient wears a device
|
|
|
Outcomes of the State Trait Anxiety Inventory (STAI)
Délai: Once a day during the 2-3 days the patient participantes in this study
|
Once a day during the 2-3 days the patient participantes in this study
|
|
|
Outcomes of the Pain Catastrophizing Scale (PCS)
Délai: On day 2 or 3 when patients participates in the study
|
On day 2 or 3 when patients participates in the study
|
|
|
System usability Scale
Délai: 1 year
|
1 year
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Gender
Délai: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Age
Délai: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Diagnosis
Délai: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
|
Performed surgical procedure
Délai: On day 1 when patients participates in the study
|
Extraction from EHR
|
On day 1 when patients participates in the study
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Harry van Goor, MD, PhD, FRCS, Radboud University Medical Center
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système digestif
- Tumeurs par type histologique
- Tumeurs
- Tumeurs par site
- Adénocarcinome
- Carcinome
- Tumeurs, glandulaires et épithéliales
- Maladies du système endocrinien
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies gastro-intestinales
- Tumeurs des glandes endocrines
- Maladies du côlon
- Maladies intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies pancréatiques
- Tumeurs canalaires, lobulaires et médullaires
- Tumeurs pancréatiques
- Carcinome canalaire
- Tumeurs colorectales
- Carcinome canalaire pancréatique
Autres numéros d'identification d'étude
- HEEL-2015-03
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .